Cytovance Biologics, Inc. has partnered with NeuroFx to develop and manufacture stem cell derived, cell-free therapy for neurological conditions. NeuroFx has selected Cytovance to develop a therapeutic factor concentrate platform and program to deliver a robust development and manufacturing process.
 
Brian Johnstone Ph.D., director of R & D at NeuroFx, said, "Recognition of the critical function of mesenchymal stem cells' (MSC) paracrine factors has prompted investigation into many different disease models of conditioned medium (CM) obtained from culturing MSC. Studies in rodent stroke models have validated the therapeutic potential of adipose stem/stromal cell (ASC) as well as MSC-derived therapeutic factors, demonstrating a similar effect as with cell delivery."
 
John Conner, vice president of Manufacturing Operations at Cytovance Biologics, said, "We are excited to work together with NeuroFx to develop and manufacture a cell free therapeutic for neurological conditions based on a MSC-CM platform."